Early data from the faridoxorubicin (FAP-Dox, AVA6000) Phase Ib SGC (salivary gland cancers) cohort (n=19) show durable tumour shrinkage and are consistent with results seen in the Phase Ia (n=11) cohort. DCR (disease control rate) remains high at 90%. The median PFS (progression free survival) has yet to be reached but, at over nine months, is already over double the benchmark 3.5-4.0 months seen for conventional therapy in pre-treated SGC, and 4.0-6.5 months in first-line SGC.
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
